Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 January 2020 | Story Rulanzen Martin | Photo Pexels
Conference
At the meet-and-greet last night, were from left Prof Ruad Ganzevoort, Diversity Officer and Dean of Theology and Religion at VUA, Prof Francis Petersen and Dr Gene Block, Chancellor of UCLA.

The Unit for Institutional Change and Social Justice at the University of the Free State (UFS) is hosting a colloquium on Fragility and Resilience: Facets, Features and Transformation in Higher Education which started on 29 January, with the official progamme concluding on 30 January 2020.

The colloquium is a annual collaborative partnership between the UFS, University of California, Los Angeles (UCLA), and the Vrije Universiteit Amsterdam (VUA).

Apart from the overarching themes the colloquium also placed some focus on mental health, within this context as all three regions are witnessing a spike in mental health issues among students and staff as well as a deficit in terms of being able to sufficiently address the crisis.

“All three universities are committed to discussing global developments in diversity and transformation in higher education to discussing global developments in diversity and transformation as it may constitute itself in higher education circles around the globe,” says Dr Dionne van Reenen, convener of the 2020 colloquium and research fellow at the unit.  

The idea is to discuss what has and has not worked and, hopefully, access best practices in a variety of contexts. The partnership between the three universities spans over six years starting in 2014 when the UFS first hosted the research colloquium. It is the third time the UFS has hosted the colloquium.
 
Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, along with other members of the UFS Rectorate, attended a meet-and-greet on Monday 28 January 2020, and was joined by Dr Gene Block, Chancellor of UCLA, Vice Provosts Cindy Fan, Patricia Turner, Charles Alexander, Professors Abel Valenzuela, John Hamilton and Dr Shalom Staub, director of Community Learning, as well as Prof Ruard Ganzevoort, Chief Diversity Officer and Dean of Theology and Religion at VUA 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept